Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 ...

A new study from UCLA Health shows that a cardiovascular risk score already used routinely in primary care can predict who ...

Samsung Bioepis has begun direct commercialization of Byooviz in Europe. Byooviz is a biosimilar to Lucentis’ (ranibizumab).

BENGALURU: Across Bengaluru and several other cities, ophthalmologists reported that there is a steady rise in diabetic ...

Samsung Bioepis has started direct commercialisation of Byooviz, a biosimilar to Genentech’s Lucentis (ranibizumab), in ...

Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ ®, a biosimilar to Lucentis 1 (ranibizumab), in Europe. Samsung Bioepis has been working to ...